drugset / Trial / NCT01595321
Pancreatic Tumor Cell Vaccine (GVAX), Cyclophosphamide, SBRT, and FOLFIRINOX in Patients With Resected Adenocarcinoma of the Pancreas
Phase 2
Completed
19 enrolled
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
The Skip Viragh Foundation · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to estimate safety of GVAX Pancreas Vaccine (GVAX) with immune modulating doses of cyclophosphamide (Cy) followed by SBRT and FOLFIRINOX chemotherapy in pancreatic cancer patients after surgery.
Timeline
- Start
- 2012-10-29
- Primary completion
- 2023-10-18
- Completion
- 2023-10-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclophosphamide | Other / unclassified | 200 mg/m2 | — |
| Subject | GVAX Pancreas Vaccine | Vaccine | 5e+08 cells | Intramuscular |
| Subject | Irinotecan | Small molecule | 180 mg/m2 | Intravenous |
| Subject | Leucovorin | Small molecule | 400 mg/m2 | Intravenous |
| Subject | Oxaliplatin | Small molecule | 85 mg/m2 | Intravenous |
| Subject | fluorouracil | Small molecule | 2400 mg/m2 | Intravenous |